General trend and business model innovation of health care industry

Source: scientific research dynamic monitoring express September 9, 2014 global pharmaceutical industry has been reshaped from product orientation to effectiveness and value orientation, which is a change caused by patients and payers For the pharmaceutical innovation system, in such a rapidly changing situation, to understand the impact of this profound change will face many challenges and problems For example, how long does it take to shift to results and value? How to understand the complex and changing market structure? To what extent and in what way should pharmaceutical enterprises break through the product itself? In the progress 2014 report released by Ernst & Young in May 2014, the answers to these important questions are given The report focuses on the pace of change in key markets and finds that many areas are developing rapidly, including healthcare reform, data analysis, patient information enabling technology, etc.; it summarizes findings from a survey of U.S payers, European payers and pharmaceutical companies, emphasizing the gap between the pharmaceutical industry and payers; it provides a A structural approach to deal with the complex and fragmented payment market structure of medical products, i.e strategic payer engagement framework, enables companies to screen, differentiate and rank patients and solutions The report recommends taking the necessary actions in important, payer related areas, including developing consumer centric solutions, developing data-driven thinking and initiatives, and rebuilding trust From the content of this report, there are several points worthy of attention from the medical science and technology circles and industry circles of our country: first, to grasp the development trend of the medical market in the next 5-10 years, we need to pay full attention to the important role of patients, especially the payers of medical expenses, in reshaping the industrial system For the pattern of traditional large-scale pharmaceutical enterprises recessively dominating the health care market and the ever inclined "balance of medical system", the new trend means that the participants in the health care market will be more extensive, consumers and payers of medical expenses will have more say, and the game of all parties involved in the health care market will be more balanced in the future Therefore, although the scale of the healthcare industry will further expand or even grow rapidly, the industry profits may not be unique compared with most other traditional industries Of course, the great changes of medical model brought by the scientific and technological revolution will not be excluded in the future, so that the scientific and technological personnel or medical service production and supply enterprises can regain the market dominance, but the trend of further strengthening the roles of patients and medical payers will be inevitable Second, we need to pay attention to the great benefits of the new medical health model for the transformation of medicine From Pharma 1.0 to Pharma 2.0, to Pharma 3.0 and even further to other modes, the driving force of the transformation of medical health mode comes from the new technology and the reform of medical system in the final analysis All kinds of manifestations of the new medical health model and the significant progress of the reform of the medical system are related to improving the bargaining power of various participants, especially the buyer, which has a profound impact on breaking the invisible obstacles faced by the development of translational medicine and promoting the development of translational medicine Third, the business model innovation of pharmaceutical enterprises will flourish, and its impact may even be traced back to the results of scientific research institutions, professional transfer mode and industrial cooperation mode In the face of the general trend of diversified customers and various personalized needs, not only traditional pharmaceutical enterprises and health care product service providers need to transform through new business models, but also the achievement transformation transfer model and industry cooperation model of innovation value chain upstream scientific research institutions may need to be constantly adjusted to adapt to the fast and dynamic market With value creation as the core, the commercialization experiment, value approach, business model canvas, using behavioral economics approach, expanding (customer-centric) solutions, and developing data-driven thinking and initiatives mentioned in the report will be the beginning of new business model innovation Fourth, the generalization of the concept of health care is a new opportunity for the development of the medical insurance industry, which will help to further expand the social influence of the medical care industry On the face of it, this report looks at the payment market, but it has a broader meaning, including traditional payers (insurance companies and government agencies), as well as other people who are actually becoming payers (for example, many medical service providers and enterprise employers) In the new health care system, financial risks are widely shared, and the boundaries between different institutions become very blurred However, it should be noted that since the transformation to achievements and values is mainly led by those institutional payers, the market of self funded medical services and products will not be affected by these new trends soon, and its future development is worth observing.